HBA names new president, executive committee members

The Healthcare Businesswomen's Association (HBA) elected Barbara
Pritchard, president of The Pritchard Group, as the association president. Debra Newton, president and chief executive of Newton Edge, was named president-elect. The HBA also announced the
members of its 2005 executive committee: first vice president, Patricia Pesanello, chief knowledge strategist for pharmaceuticals and health sciences, BusinessEdge Solutions; second vice president, Elizabeth Mutisya, vice president, medical affairs, Cephalon; treasurer Cathy Kerzner, vice president, strategic development, Cardinal Health -- Medical Education Services; secretary Christine Zak, director of customer marketing, Roche Laboratories; and immediate past president Daria Blackwell, president, Knowledge Clinic. Other new board members include: past president, Nancy Larsen, president, PROmedica Communications; and the following directors-at-large: Lisa Courtade, director, global marketing analytics metabolism, Sanofi-Aventis; Linda DaSilva, director,
pharmacy and trade relations, Eisai;Kimberly Farrell, president, Unlimited Performance Training; and Ilyssa Levins, managing partner, GCI/Brand Edge.
You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.